Grace Therapeutics (GRCE) Stock Forecast: StockMap's 2-Week Call
GRCE stock forecast: StockMap's model makes no two-week call on Grace Therapeutics after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Right in 3 of 6 two-week windows on GRCE since Aug 21; by chance, a call on the same dates was right 58% of the time.
Grace Therapeutics last closed at $1.73, +0.00% on the session.
Against the IVW growth benchmark the position is +2.33% over the forecast window.
Grace Therapeutics' market cap is $36.39M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).
Where GRCE sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
38 daily calls for GRCE so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Grace Therapeutics in the 22nd percentile on return on equity, where 100 is best.
Grace Therapeutics is classified under Health Care / Pharmaceuticals.
StockMap tracks Grace Therapeutics as the 113th largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Grace Therapeutics ranks 29th of 153 in the group, against a group median of -0.36.